Trevi Therapeutics (TRVI) Amortizatization of Intangibles (2022 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Amortizatization of Intangibles of $431000.0 for Q1 2026, up 9.11% year-over-year from $395000.0 in Q1 2025, and down 23.31% quarter-over-quarter from $562000.0 in Q4 2025.
Powered by 
Analysis
Trevi Therapeutics (TRVI) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Trevi Therapeutics' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $431000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 9.11% year-over-year to $431000.0; the TTM figure through Mar 2026 stood at $1.7 million (up 21.22% YoY), while the FY2025 annual figure was $1.6 million, up 19.82% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $431000.0, down from $562000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $671000.0 in Q1 2023, with the low at $196000.0 in Q3 2022.
- The 5-year median for Amortizatization of Intangibles is $383000.0 (2025), against an average of $421200.0.
- The sharpest annual moves came in 2023 and 2024: Amortizatization of Intangibles surged 140.82% in 2023, then tumbled 46.75% in 2024.
- Trevi Therapeutics' Amortizatization of Intangibles stood at $561000.0 in 2022, then slumped by 37.43% to $351000.0 in 2023, then decreased by 15.38% to $297000.0 in 2024, then surged by 89.23% to $562000.0 in 2025, then slipped by 23.31% to $431000.0 in 2026.
- Business Quant data shows TRVI's Amortizatization of Intangibles at $431000.0 in Q1 2026, $562000.0 in Q4 2025, and $298000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Trevi Therapeutics | 2.71 Bn | 2.71 Bn | - | 517,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 517,000.00 |
| Mar 31, 2026 | 431,000.00 |
| Dec 31, 2025 | 562,000.00 |
| Sep 30, 2025 | 298,000.00 |
| Jun 30, 2025 | 383,000.00 |
| Mar 31, 2025 | 395,000.00 |
| Dec 31, 2024 | 297,000.00 |
| Sep 30, 2024 | 353,000.00 |
| Jun 30, 2024 | 336,000.00 |
| Mar 31, 2024 | 381,000.00 |
| Dec 31, 2023 | 351,000.00 |
| Sep 30, 2023 | 472,000.00 |
| Jun 30, 2023 | 631,000.00 |
| Mar 31, 2023 | 671,000.00 |
| Dec 31, 2022 | 561,000.00 |
| Sep 30, 2022 | 196,000.00 |